Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma

LESSONS LEARNED. Trebananib leveraging anti‐angiogenic mechanism that is distinct from the classic sorafenib anti‐vascular endothelial growth factor inhibition did not demonstrate improved progression‐free survival at 4 months in patients with advanced hepatocellular carcinoma (HCC). In support of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Abou‐Alfa, Ghassan K., Blanc, Jean‐Frederic, Miles, Steven, Ganten, Tom, Trojan, Jörg, Cebon, Jonathan, Liem, Andre K., Lipton, Lara, Gupta, Charu, Wu, Benjamin, Bass, Michael, Hollywood, Ellen, Ma, Jennifer, Bradley, Margaret, Litten, Jason, Saltz, Leonard B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507650/
https://www.ncbi.nlm.nih.gov/pubmed/28592620
http://dx.doi.org/10.1634/theoncologist.2017-0058

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507650/
https://www.ncbi.nlm.nih.gov/pubmed/28592620
http://dx.doi.org/10.1634/theoncologist.2017-0058

Ejemplares similares